Schulman IRB supports this initiative with StudyKIK because they have created an easy platform for patients to search and find
Costa Mesa, California (PRWEB) April 07, 2016
StudyKIK, a company that connects people interested in joining a clinical trial find local study information in the safest way possible, announces their initiative on creating clinical trial industry standards reviews and approvals of digital clinical trial advertisements by Institutional Review Boards (IRBs). The review process for any type of clinical trial advertisement for the purpose of patient recruitment is an extremely important process because the information displayed about the clinical trial must be done so in a safe and non-coercive manner for the potential volunteers.
The current landscape is comprised of numerous IRBs that have different viewpoints and interpretations of the FDA guidelines for clinical trial advertisements and how digital media should be used. These different interpretations can lead to prolonged study start up and uncertainty for future delays when additional approvals are needed. With the large growth of digital media being used for clinical trial patient recruitment, StudyKIK has connected with many of the leading IRBs in the clinical trial industry that are focused on speeding up study start-up times and patient enrollment through digital advertising in an effort to get these new treatments tested as quickly as possible for those who are in need of them. The “Digital Review Standard Initiative” was started to create a standard for what content and layout is acceptable when recruiting for clinical trial volunteers online. To start the initiative, StudyKIK has had their website and the way they display approved clinical trial information approved in the form of template by IRBs that are leading the industry in patient safety and digital understanding.
The IRBs that have chosen to work with StudyKIK on this initiative are the leaders in overseeing compliance with clinical regulation and have the highest understanding of digital patient recruitment in the industry. Some of these IRBs include Integreview IRB, Schulman IRB, Sterling IRB, and Alpha IRB. These IRBs worked with StudyKIK to review the entire StudyKIK website and the way research sites display clinical trial advertisements and have given their overall approval, so additional approvals are not needed when they are the managing IRB on a specific clinical trial. Pharmaceutical companies choose to work with these IRBs because they take patient safety to the highest importance while having the quickest study start up time in the industry.
Rebecca Ballard, Vice President of Compliance and Board Operations at Schulman IRB, the industry-leading central IRB in customer service and technology stated:
“Schulman IRB understands that the digital landscape is changing the way clinical trial advertisements are displayed to potential volunteers. We support this initiative with StudyKIK because they have created an easy platform for patients to search and find reliable, IRB-approved information.”
By creating these standardizations in the industry, more people who need treatment will may be able to get involved in cutting edge clinical trials that may can quickly advance today’s drug development.